

For Immediate Release



ASX Announcement

26 October, 2026
Melbourne, Australia

Brian McNamee to retire: Gordon Naylor appointed next Chair of CSL

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that Dr Brian McNamee AO will retire from the Board of CSL Limited on 31 March 2027.

Following a thorough process, the Board of Directors has unanimously decided that the person best placed, most qualified and trusted to lead them is Mr Gordon Naylor, who has been elected as the next Chair of CSL, also effective from 31 March 2027.

Mr Naylor is a highly experienced non-Executive Director and a proven former senior executive of CSL who has been CSL's Interim CEO and Managing Director since February 2026.

As previously announced, Mr Naylor will continue in this role until 1 February 2027. After conducting a thoughtful and orderly transition with Ms Deborah Waterhouse (CSL's incoming Chief Executive), Mr Naylor will resume his role on the Board as a non-Executive Director, and as Chair Elect.

The Board of Directors has also appointed Ms Carolyn Hewson AO in the role of Senior Independent Director, also effective from 31 March 2027. This appointment recognises that Mr Naylor will not be initially considered as an independent Board Chair due to his executive role with CSL over the 12 months prior to stepping into the Board Chair role.

Ms Hewson said, "The Board acknowledges and celebrates Brian's enormous contribution to CSL since the company's inception. Brian's significant influence and legacy are seen through the long-term positive impact on our donors, patients, employees and shareholders and as a result they are difficult to overstate."

"Brian leaves big shoes to fill and few people understand plasma, vaccines and this company as well as Gordon. That is why the Board chose to move forward into CSL's next chapter with Gordon as its Chair. His extensive career at CSL gives him unique knowledge and insight to assume this role and his experience as a director will ensure strong governance and oversight on behalf of shareholders."

Authorised for lodgement by:

Fiona Mead
Company Secretary



Investor Relations

Michelle Rees

P: +61 410 600 745

E: michelle.rees@csl.com.au



Media Relations

Brett Foley

P: +61 461 464 708

E: brett.foley@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000
